4 180

Cited 81 times in

Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry.

Authors
 Seho Parka  ;  Ja Seung Koo  ;  Min Suk Kim  ;  Hyung Seok Park  ;  Jun Sang Lee  ;  Jong Seok Lee  ;  Seung Il Kim  ;  Byeong-Woo Park 
Citation
 Breast, Vol.21(1) : 50-57, 2012 
Journal Title
 Breast 
ISSN
 0960-9776 
Issue Date
2012
Abstract
To investigate the significance of immunohistochemical molecular subtyping, we evaluated outcomes of subtypes based on estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and Ki-67. Using tissue microarrays, 1006 breast cancer patients between November 1999 and August 2005 were categorized into four subtypes: luminal A (ER+ and/or PR+, HER2-, Ki-67 < 14%), luminal B (ER+ and/or PR+, HER2-, Ki-67 ≥ 14% or ER+ and/or PR+, HER2+), HER2-enriched (ER-, PR-, HER2+), and triple-negative breast cancer (TNBC) (ER-, PR-, HER2-). Demographics, recurrence patterns, and survival were retrospectively analyzed using uni-/multivariate analyses. Luminal A, luminal B, HER2-enriched, and TNBC accounted for 53.1%, 21.7%, 9.0%, and 16.2% of cases, respectively. Luminal A presented well-differentiation and more co-expression of hormone receptors comparing to luminal B. HER2-enriched showed larger size and higher nodal metastasis. TNBC demonstrated younger age at diagnosis, larger size, undifferentiation, higher proliferation, and frequent visceral metastases. The peak of recurrence for luminal A was at 36 months postoperatively, while that for HER2-enriched and TNBC peaked at 12 months. The relapse risk of luminal B was mixed. Luminal A showed the best survival, but no difference was observed between the other three subtypes. When matched by nodal status, however, TNBC showed the worst outcomes in node-positive patients. In multivariate analyses, luminal A remained a positive prognostic significance. Immunohistochemically-defined subtypes showed different features, recurrence patterns, and survival. Therefore, molecular subtypes using four biomarkers could provide clinically useful information of tumor biology and clinical behaviors, and could be used for determining treatment and surveillance strategies.
Full Text
http://www.sciencedirect.com/science/article/pii/S0960977611001585
DOI
10.1016/j.breast.2011.07.008
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers
Yonsei Authors
구자승(Koo, Ja Seung) ORCID logo https://orcid.org/0000-0003-4546-4709
김승일(Kim, Seung Il)
박병우(Park, Byeong Woo) ORCID logo https://orcid.org/0000-0003-1353-2607
박세호(Park, Se Ho) ORCID logo https://orcid.org/0000-0001-8089-2755
박형석(Park, Hyung Seok) ORCID logo https://orcid.org/0000-0001-5322-6036
이종석(Lee, Jong Seok)
이준상(Lee, Jun Sang) ORCID logo https://orcid.org/0000-0002-4054-6900
Export
RIS (EndNote)
XLS (Excel)
XML
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/89808
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse